Dublin, Ireland, 16 August 2013
Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that its Director of Research and Development, Dr Michael O’Neill, was interviewed by Pharma Television’s Fintan Walton about its promising kinase inhibitor programs which are in development for cancer. To watch the interview, please follow the link here.
About Inflection Biosciences
Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. Based in Ireland and the UK, the Company is creating a pipeline of highly innovative cancer treatments through alliances with leading cancer research organisations. The pipeline includes a novel PIM kinase inhibitor program and a unique multi-targeting kinase inhibitor program in preclinical development. For more information please visit the Company’s website at www.inflectionbio.com
For Further Information Contact:
Darren Cunningham, Chief Executive Officer
Inflection Biosciences Ltd
+353 (0)1 4003615